Morgan Stanley maintains Ovintiv at Equal-Weight, raises price target to $72 from $71
Morgan Stanley kept its Equal-Weight rating on Ovintiv but increased its price target to $72 from $71, suggesting a 12.8% upside from the Nov 17 close of $63.84. Other recent analyst targets range from $74 to $90.


